— Know what they know.
Not Investment Advice

NVRO NYSE

Nevro Corp.
1W: -0.2% 1M: +1.9% 3M: +57.0% 1Y: -56.2% 3Y: -91.3% 5Y: -93.5%
$5.84
Last traded 2025-04-02 — delisted
NYSE · Healthcare · Medical - Devices · $224.1M mcap · 34M float · 3.80% daily turnover · Short 35% of daily vol

Cash Flow Trends

Operating Cash Flow
-$19M +67.0% ▲
Capital Expenditures
$10M -13.9% ▼
5Y CAGR: +23.0%
Free Cash Flow
-$29M +56.7% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$10M +39.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$83M-$131M$3M-$92M-$113M
Depreciation & Amort.$8M$9M$10M$12M$14M
Stock-Based Comp.$43M$44M$57M$57M$51M
Change in Working Capital$11M$16M-$49M-$40M$15M
Other Non-Cash Items$15M$13M$3M$5M$14M
Operating Cash Flow$1M-$42M$25M-$59M-$19M
— Investing Activities —
Capital Expenditures-$6M-$12M-$8M-$9M-$10M
Acquisitions (Net)$8M-$214M-$64M-$38M-$45K
Investment Purchases-$668M-$447M-$268M-$191M-$160M
Investment Sales$297M$661M$340M$231M$184M
Other Investing-$364M$214M$64M$0$0
Investing Cash Flow-$370M$202M$64M-$7M$15M
— Financing Activities —
Net Debt Issuance$190M-$172M$0$54M$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$166M-$8M-$9M-$11M-$8M
Financing Cash Flow$347M-$169M-$2M$50M-$4M
Net Change in Cash-$21M-$10M$86M-$16M-$10M
Cash End of Period$45M$35M$121M$105M$95M
Free Cash Flow-$5M-$54M$17M-$67M-$29M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms